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Abstract
The novel coronavirus, SARS-CoV-2, can present with a wide range of neurological manifestations, in both adult and pediatric
populations. We describe here the case of a previously healthy 8-year-old girl who presented with seizures, encephalopathy, and
rapidly progressive, diffuse, and ultimately fatal cerebral edema in the setting of acute COVID-19 infection. CSF analysis,
microbiological testing, and neuropathology yielded no evidence of infection or acute inflammation within the central nervous
system. Acute fulminant cerebral edema (AFCE) is an often fatal pediatric clinical entity consisting of fever, encephalopathy, and
new-onset seizures followed by rapid, diffuse, and medically-refractory cerebral edema. AFCE occurs as a rare complication of a
variety of common pediatric infections and a CNS pathogen is identified in only a minority of cases, suggesting a para-infectious
mechanism of edema. This report suggests that COVID-19 infection can precipitate AFCE, and highlights the need for high
suspicion and early recognition thereof.
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COVID-19, caused by the novel SARS-CoV-2 virus, emerged
in December 2019 causing widespread morbidity and mortal-
ity. Coronaviruses have associated neurological manifesta-
tions, as noted during the SARS (2002) and MERS (2012)
epidemics.1 Multiple neurological manifestations of
COVID-19 have been described in children, including ence-
phalitis/encephalopathy, seizure-like activity, and peripheral
weakness.2–7
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Acute fulminant cerebral edema (AFCE) is a poorly under-
stood clinical entity characterized by fever, encephalopathy
and often new seizures followed by rapid progression to diffuse
cerebral edema, with potentially fatal outcomes.8,9 Postmortem
examination of the brain in fatal cases of AFCE confirms dif-
fuse brain edema but does not reveal an underlying cause, such
as meningitis, encephalitis, brain infarcts, hypoxic-ischemic
encephalopathy, or toxic/metabolic encephalopathy.8 We
report a child with acute seizures and acute fulminant cerebral
edema in the context of COVID-19 infection.
Case History
A previously healthy 8-year-old Latina female presented to our
emergency department (ED) with 1 day of fever (Tmax
100.4F), lethargy, myalgias, anorexia, and new-onset
seizure-like activity. She was diagnosed with group A strepto-
coccal (GAS) pharyngitis and COVID-19 at an urgent care
clinic, just prior to presenting to the ED. En route to retrieve
antibiotics for GAS, she developed emesis, altered conscious-
ness, and had a 2-minute, self-resolving period of seizure-like
activity, described as generalized convulsions and drooling.
The patient was previously healthy without prior hospitaliza-
tions, up-to-date on immunizations, and without known head
trauma, drug allergies, inadvertent ingestions, or daily
medications.
Her vital signs in the ED were: rectal temperature 38.9C,
heart rate 88, respiratory rate 33, blood pressure 92/69, SpO2
91% on room air. She was awake but drowsy and in no acute
distress. Neurological examination revealed mild confusion,
mildly reduced verbal output with appropriate responses to
simple questions, inconsistent ability to follow commands, no
focal motor deficits and no meningeal signs. Skin examination
revealed a pink, fine macular rash wrapping around her trunk
and upper extremities, sparing her palms/soles. She had poster-
ior pharyngeal erythema without tonsillar hypertrophy or exu-
date. The remainder of the examination was unremarkable.
The patient remained stable for a 2-hour period until
resumption of seizure activity, consisting of 1 minute of gen-
eralized convulsions followed by decorticate posturing of the
limbs, trismus, right head version, and alternating right and left
eye deviation. Pupils remained equal, round and reactive to
light throughout. She had an episode of emesis during the
seizure with suspected aspiration; her SpO2 dropped as low
as 86% but quickly corrected to > 92% on 4 L O2. Her seizures
were unresponsive to 2 doses of intravenous lorazepam (0.1
mg/kg), but terminated with a loading bolus of levetiracetam
(60 mg/kg) after 25 minutes.
Initial laboratory evaluation revealed a normocytic anemia,
slightly elevated AST, and slightly elevated C-reactive protein
(Table 1). A nasopharyngeal swab for SARS-CoV-2 RT-PCR
returned positive. After a blood culture was collected (which
ultimately revealed no growth), broad-spectrum antimicrobials
(vancomycin, ceftriaxone, and acyclovir) were initiated for
possible meningitis. Chest X-ray showed prominent right peri-
hilar and bibasilar lung markings. A non-contrast head CT
following her seizure episode in the ED showed sulcal loss
suggesting global edema, without evidence of herniation.
Given her failure to return to her baseline mental status she
was admitted to the Pediatric Intensive Care Unit (PICU) for
continuous video EEG (cvEEG) and closer monitoring.
On arrival to the PICU the patient was minimally respon-
sive, with intermittent decerebrate posturing, rhythmic upper
extremity flexion, and twitching of all 4 extremities; pupils
remained equal, round, and reactive to light bilaterally. In
response to her intermittent rhythmic movements, she received
3 additional doses of lorazepam 0.04 mg/kg (spaced 10-15
minutes apart) while awaiting a fosphenytoin loading dose.
cvEEG - initiated within 1 hour of PICU arrival - revealed a
symmetric but attenuated background, without epileptiform
activity. She experienced short episodes of hypertension and
tachycardia but was never bradycardic, nor persistently hyper-
tensive. Her respiratory rate declined approximately 1 h after
arrival to the PICU, requiring emergent intubation, at which
time she had no cough or gag reflex. Post-intubation, she devel-
oped fluid-refractory hypotension necessitating inotropic and
vasopressor support. She had no response to painful stimuli on
central line placement and her pupils were fixed and dilated
(1.5 hours into her PICU stay). She then received hypertonic
saline and mannitol given concern for elevated intracranial
pressure (ICP). After stabilization, she was taken emergently
for a brain MRI, which revealed diffuse cerebral edema, slit-
like lateral ventricles, crowding of the basilar cisterns and early
downward herniation with kinking at the spinomedullary junc-
tion. There was no restricted diffusion. MRA demonstrated
absent or minimal flow beyond the proximal segments of the
major cerebral arteries, consistent with elevated ICP limiting
cerebral perfusion. Also noted were mild, diffuse T2/FLAIR
hyperintensities throughout both the deep and superficial
gray matter suggesting a global, gray matter-focused process
(Figure 1). She received IV dexamethasone in attempts to
reduce cerebral edema. Post-MRI, she developed pulseless
ventricular tachycardia requiring 2 minutes of CPR before
return of spontaneous circulation. Regarding immunomodula-
tory therapy, she received intravenous immunoglobulin
(2 g/kg), anakinra, and hydrocortisone; despite approval for
remdesivir and COVID-19 convalescent plasma, these were
ultimately withheld due to poor prognosis. Brain death exam-
inations at 24 and 48 hours post-cardiac arrest were consistent
with brain death. Repeat MRI between brain death examina-
tions showed further limited cerebral perfusion and progression
of uncal/tonsillar herniation. She was pronounced dead at the
time of the second brain death examination.
Lumbar puncture performed immediately post-mortem
yielded clear CSF with normal glucose (64 mg/dL), highly
elevated protein (>1,500 mg/dL), 1 RBC, and 4 nucleated cells
(50% neutrophils, 11% lymphocytes), indicating no encephali-
tis or meningitis. CSF culture was negative for bacteria and
fungi. Extensive infectious disease testing was unrevealing for
a cause of death (Table 1). Postmortem brain examination
demonstrated global brain edema with mass effect leading to
transtentorial herniation, rare red neurons in the cerebrum and
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Table 1. Initial Laboratory* and Microbiological Findings.
Parameter Patient’s value Units Reference value
Complete Blood Count
White blood cell count 6.9 109/L 4.5-13.0
Hemoglobin 10.6 g/dL 13.0-16.0
MCV 83.4 fL 78.0-98.0
Platelet count 183 109/L 150-440
Complete metabolic panel
Sodium 143 mmol/L 135-145
Potassium 4.3 mmol/L 3.4-4.7
Chloride 105 mmol/L 98-107
CO2 22.0 mmol/L 22.0-30.0
BUN 12 mg/dL 5-17
Creatinine 0.39 mg/dL 0.30-0.90
Anion gap 16 mmol/L 7-15
Glucose 128 mg/dL 70-179
Calcium 9.0 mg/dL 8.8-10.8
Magnesium 2.0 mg/dL 1.6-2.2
Phosphorus 3.9 mg/dL 4.0-5.7
Albumin 4.1 g/dL 3.5-5.0
Total Protein 7.9 g/dL 6.5-8.3
Total Bilirubin 0.2 mg/dL 0.0 -1.2
AST 53 U/L 10-40
ALT 37 U/L <50
Alkaline Phosphatase 132 U/L 130-560
Cardiac Enzymes
Troponin I <0.034 ng/mL <0.034
Pro-BNP 547.0 pg/mL 0.0-178.0
ESR 19.0 mm/h 0-20
CRP 19.1 mg/L <10.0
LDH 742 U/L 380-770
Coagulation Panel
PT 14.4 sec 10.2-13.1
INR 1.25 N/A N/A
APTT 36.5 sec 25.9-39.5
D-Dimer 3,493 DDU <230
Fibrinogen 316 mg/dL 177-386
Infectious Disease Test Results
SARS-CoV-2 PCR (nasopharyngeal) Positive N/A Negative
SARS-CoV-2 PCR (CSF) Negative N/A Negative
Blood culture No growth N/A No growth
CSF culture No growth N/A No growth
4th generation HIV Ag/Ab Negative N/A Negative
CMV PCR (serum and CSF) Undetectable N/A Undetectable
EBV PCR (serum and CSF) Undetectable N/A Undetectable
HHV-6 PCR (serum and CSF) Undetectable N/A Undetectable
HSV 1/2 PCR (serum and CSF) Undetectable N/A Undetectable
VZV PCR (serum and CSF) Undetectable N/A Undetectable
Enterovirus PCR (serum and CSF) Undetectable N/A Undetectable
Arbovirus panel (CSF) Negative N/A Negative
Parvovirus B-19 PCR (serum) Undetectable N/A Undetectable
Bartonella antibody panel (serum) Negative N/A Negative
LCMV PCR/antibody (serum and CSF) Negative N/A Negative
Naegleria PCR (CSF) Undetectable N/A Undetectable
Balamuthia PCR (CSF) Undetectable N/A Undetectable
Acanthamoeba PCR (CSF) Undetectable N/A Undetectable
Baylisascaris procyonis Ab (serum) Negative N/A Negative
Postmortem Microbiological Results
Aerobic culture, left lung Candida parapsilosis1, Lactobacillus N/A No growth
Aerobic culture, right lung No growth N/A No growth
Aerobic culture, brain tissue <1þ Candida parapsilosis2 N/A No growth
Aerobic/anaerobic culture, spleen No growth N/A No growth
AFB smear/culture, left lung No growth N/A No growth
(continued)
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Table 1. (continued)
Parameter Patient’s value Units Reference value
AFB smear/culture, right lung No growth N/A No growth
AFB smear/culture, brain tissue No growth N/A No growth
Fungal culture, left lung 4þ Candida parapsilosis1 N/A No growth
Fungal culture, right lung No growth N/A No growth
Fungal culture, brain tissue No growth N/A No growth
Respiratory pathogen panel, left lung Negative N/A Negative
Respiratory pathogen panel, right lung Negative N/A Negative
SARS-CoV-2 PCR (blood) Negative N/A Negative
SARS-CoV-2 PCR (brain tissue) Negative N/A Negative
SARS-CoV-2 PCR (left lung) Negative N/A Negative
SARS-CoV-2 PCR (right lung) Negative N/A Negative
* Initial laboratory findings obtained while patient was in the emergency department.
1This fungal growth was likely related to the patient’s known aspiration event.
2Growth from aerobic culture of brain tissue was believed to be contamination from lung tissue at time of autopsy; growth in only 1 of 2 aerobic cultures
from brain tissue.
Figure 1. Brain imaging (MRI/MRA/MRV). day #1 brain MRI (A) sagittal T1 image demonstrates downward herniation with decreased size of the
suprasellar cistern, posterior fossa crowding causing brainstem compression against the clivus and developing tonsillar herniation. (B) MRV
demonstrates patent jugular veins and transverse sinuses without thrombosis. The sagittal sinus and deep venous system are not visible. (C) T2
axial images reveal diffuse cortical swelling mild, global gray matter hyperintensity, and slit-like ventricles suggesting brain edema. (D) coronal
MRA image demonstrates near complete or complete loss ACA, MCA, PCA and basilar flow. (E) susceptibility-weighted imaging shows
exaggerated cortical veins consistent with engorgement vs thrombosis. the subsequent MRI sagittal T1 (F), day #2 demonstrates tonsillar
herniation down to the level of C2. MRIs on day #1 and 2 revealed bilateral parotid cysts (G), suggesting parotitis, which has been reported in
cases of COVID-19 infection.21,22
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cerebellum consistent with acute ischemic neuronal necrosis,
and a very small number of chronic inflammatory cells in the
leptomeninges and around a few intraparenchymal blood ves-
sels. There was no evidence of encephalitis, large- or small-
vessel vasculitis or thrombosis, or perivascular demyelination.
Findings of chronic lymphocytic thyroiditis on autopsy and
parotid cysts on brain MRI raised concerns for a possible
underlying autoimmune condition. Thyroid testing performed
on salvaged serum revealed an elevated TSH (8.924 uIU/mL;
reference range 0.50-4.50) with normal free T4 (1.62 ng/dL;
reference range 0.8-2.0). Thyroid antibodies were unable to be
sent. Parents reported no known underlying medical/autoim-
mune conditions and no family history of autoimmune disease.
Postmortem lung cultures grew Candida parapsilosis, likely
related to the aspiration event. The remainder of the postmor-
tem cultures were unremarkable (Table 1). CSF, blood, brain
tissue, and bilateral lungs were negative for SARS-CoV-2
RNA by RT-PCR.
Discussion
The pathogenetic mechanisms of the diverse neurological man-
ifestations of COVID-19 are uncertain, though the ability of
SARS-CoV-2 to invade cells using the ACE2 receptor has been
confirmed.10 AFCE is characterized clinically by rapidly
increasing ICP with neurological deterioration (GCS < 8, signs
and symptoms of brainstem dysfunction) while imaging
demonstrates cerebral edema and herniation. This is a rarely
described but often fatal acute encephalopathic process,8,9,11 of
which the majority of cases are associated with preceding sei-
zures. In this case, the fulminant cerebral edema seems neither
a direct viral effect, given the absence of SARS-CoV-2 RNA in
the CSF and brain parenchyma, nor secondary to encephalitis,
evidenced by the lack of inflammation on CSF indices and on
neuropathological examination. Similarly, both cohorts of
AFCE described to date note a variety of associated common
pediatric infections, with a CNS pathogen identified in only a
minority of cases. The heterogeneity of infections associated
with AFCE suggests a gene-environment interaction in which
common infections precipitate this phenotype in susceptible
individuals.
Considering other potential etiologies of the patient’s dif-
fuse cerebral edema, global hypoxic-ischemic encephalopa-
thy seems unlikely given her continuous SpO2 monitoring
and telemetry without prolonged desaturations or cardiac
arrest prior to her precipitous neurological decline. Status
epilepticus is also an unlikely etiology, as seizure-related cer-
ebral edema is reported to develop over the course of 1 - 5
days rather than the 12 hours seen in this case.12 Arterial and
venous thromboses were excluded at autopsy. Despite con-
firmed GAS pharyngitis, the lack of bacterial meningitis, bac-
teremia, or acute inflammation at postmortem examination
suggests that bacterial pathogens did not directly cause her
decline. The very scant chronic perivascular and leptomenin-
geal inflammation seen on autopsy is nonspecific, does not
suggest a para-infectious cerebritis or vasculitis, and likely
represents an inflammatory reaction to the brain ischemia
associated with her prolonged increased intracranial pressure.
Her markedly elevated CSF protein is nonspecific and con-
founded by the timing of lumbar puncture relative to cerebral
anoxia. The chronic lymphocytic thyroiditis on autopsy and
parotid cysts on MRI raise the possibility of an unrecognized
autoimmune disease contributing to the severity of her case,
however we were limited in the volume of scavenged blood
remaining for additional etiologic testing. The pathologic sys-
temic immune response and cytokine storm in SARS-CoV-2
infection is an increasingly recognized mediator of severe
COVID-19 infection,13–16 and the same deranged immune
response has been associated with diffuse cerebral edema,
both within the context of acute viral infection17 and with-
out.18 Finally, it has been hypothesized that perturbations of
energy metabolism through mitochondrial fatty acid oxida-
tion may lead to adenosine triphosphate utilization failure and
cytotoxic brain edema.17,19
While much remains uncertain about the pathophysiological
mechanisms of COVID-19 and AFCE, this case shows that
SARS-CoV-2 childhood infection may present with AFCE in
previously healthy children. This presentation is distinct from a
previously reported case of fatal cerebral edema in child with
SARS-CoV-2,20 in which elevated intracranial pressure devel-
oped in the context of SARS-CoV-2-associated multisystem
inflammatory syndrome. In that case, neuropathology showed
diffuse inflammation, while we did not find evidence of sig-
nificant brain pathology on postmortem examination. Addi-
tionally, encephalopathy was part of our patient’s initial
presentation. The previously reported case shows that fatal
cerebral edema may complicate pediatric multisystem inflam-
matory syndrome, while our case indicates that COVID-19
infection may directly trigger AFCE. The rapid and devastating
clinical course in both of these cases highlights the need for
early recognition of a cerebral edema and AFCE as potential
complications of COVID-19 in pediatric patients.
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